News from AHA 2024: ENBALV trial; edoxaban vs. warfarin

Chisato Izumi at AHA

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

AHA exists 100 years: What can we possibly expect in the next century?
AHA exists 100 years: What can we possibly expect in the next century?
AHA 2024
AHA exists 100 years: What can we possibly expect in the next century?
- Keith Churchwell, MD
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
AHA 2024
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
Semaglutide reduces MACE in patients with obesity or overweight and prior CABG
Semaglutide reduces MACE in patients with obesity or overweight and prior CABG
AHA 2024
Semaglutide reduces MACE in patients with obesity or overweight and prior CABG
- Subodh Verma, MD, PhD
Audit and feedback strategy for pharmacists improves HF care
Audit and feedback strategy for pharmacists improves HF care
AHA 2024
Audit and feedback strategy for pharmacists improves HF care
- Alexander Sandhu, MD